1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Lymphangioleiomyomatosis - Pipeline Review, H1 2014

Lymphangioleiomyomatosis - Pipeline Review, H1 2014

  • January 2014
  • -
  • Global Markets Direct
  • -
  • 44 pages

Lymphangioleiomyomatosis - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, 'Lymphangioleiomyomatosis - Pipeline Review, H1 2014', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Lymphangioleiomyomatosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lymphangioleiomyomatosis. Lymphangioleiomyomatosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Lymphangioleiomyomatosis.
- A review of the Lymphangioleiomyomatosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Lymphangioleiomyomatosis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Lymphangioleiomyomatosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Lymphangioleiomyomatosis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Lymphangioleiomyomatosis - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Lymphangioleiomyomatosis Overview 6
Therapeutics Development 7
Pipeline Products for Lymphangioleiomyomatosis - Overview 7
Pipeline Products for Lymphangioleiomyomatosis - Comparative Analysis 8
Lymphangioleiomyomatosis - Therapeutics under Development by Companies 9
Lymphangioleiomyomatosis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Lymphangioleiomyomatosis - Products under Development by Companies 13
Lymphangioleiomyomatosis - Companies Involved in Therapeutics Development 14
AstraZeneca PLC 14
Novartis AG 15
Circadian Technologies Limited 16
Therametrics holding AG 17
Nobelpharma Co., Ltd. 18
Lymphangioleiomyomatosis - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 25
Assessment by Therapeutic Class 27
Drug Profiles 29
sirolimus - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
everolimus - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
VGX-200 Series - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
DasKloster-008001 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Drug For Lymphangioleiomyomatosis - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Lymphangioleiomyomatosis - Recent Pipeline Updates 37
Lymphangioleiomyomatosis - Dormant Projects 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44

List of Tables

Number of Products under Development for Lymphangioleiomyomatosis, H1 2014 7
Number of Products under Development for Lymphangioleiomyomatosis - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Late Stage Development, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Lymphangioleiomyomatosis - Pipeline by AstraZeneca PLC, H1 2014 14
Lymphangioleiomyomatosis - Pipeline by Novartis AG, H1 2014 15
Lymphangioleiomyomatosis - Pipeline by Circadian Technologies Limited, H1 2014 16
Lymphangioleiomyomatosis - Pipeline by Therametrics holding AG, H1 2014 17
Lymphangioleiomyomatosis - Pipeline by Nobelpharma Co., Ltd., H1 2014 18
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Stage and Target, H1 2014 21
Number of Products by Stage and Mechanism of Action, H1 2014 23
Number of Products by Stage and Route of Administration, H1 2014 24
Number of Products by Stage and Molecule Type, H1 2014 26
Number of Products by Stage and Therapeutic Class, H1 2014 28
Lymphangioleiomyomatosis Therapeutics - Recent Pipeline Updates, H1 2014 37
Lymphangioleiomyomatosis - Dormant Projects, H1 2014 42

List of Figures

Number of Products under Development for Lymphangioleiomyomatosis, H1 2014 7
Number of Products under Development for Lymphangioleiomyomatosis - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Early Stage Products, H1 2014 12
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Top 10 Target, H1 2014 20
Number of Products by Stage and Top 10 Target, H1 2014 21
Number of Products by Top 10 Mechanism of Action, H1 2014 22
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 23
Number of Products by Stage and Top 10 Route of Administration, H1 2014 24
Number of Products by Top 10 Molecule Type, H1 2014 25
Number of Products by Stage and Top 10 Molecule Type, H1 2014 26
Number of Products by Top 10 Therapeutic Class, H1 2014 27
Number of Products by Stage and Top 10 Therapeutic Class, H1 2014 28

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.